Piper Sandler & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Piper Sandler & Co’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-75	Closed	-$1K	–	18
2018 Q1	$1K	Buy	+75	New	+$1.6K	﹤0.01%	14

Other funds holding SGMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Piper Sandler & Co's SGMO Position: Q2 2018 in Review

Piper Sandler & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2018, closing a stake of 75 shares — an estimated $1K sold.

Piper Sandler & Co first reported a position in SGMO in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 210 funds tracked by Wall St. Rank hold SGMO as of Q2 2018.

Piper Sandler & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2018 after selling out during the quarter.
Piper Sandler & Co sold 75 SANGAMO THERAPEUTICS INC shares in Q2 2018, an estimated $1K.
Piper Sandler & Co first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 1 quarter.
Piper Sandler & Co's SANGAMO THERAPEUTICS INC position peaked at $1K in Q1 2018.
210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2018.

Based on Piper Sandler & Co's 13F filing for Q2 2018, filed 13 Aug 2018.